Catalyst
Monitor patient responses and safety data from the trial, as well as any announcements regarding dose optimization and potential expansion to larger trials.
Humanexa recommends Monitor.
Date
June 26, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.